BioCentury
ARTICLE | Clinical News

Progenics' Azedra wins FDA nod for rare NETs

August 3, 2018 5:36 PM UTC

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. The agency said Azedra is the first drug it has approved for the rare types of neuroendocrine tumors.

Azedra, a radiolabeled norepinephrine analog, is approved to treat patients ages 12 and older who require systemic therapy. It has breakthrough therapy, Orphan Drug and Fast Track status from FDA...

BCIQ Company Profiles

Progenics Pharmaceuticals Inc.